Rare Disease Report

A 45-year old with Polycythemia Vera not Responding to Hydroxyurea

SEPTEMBER 13, 2016
Srdan Verstovsek, MD, PhD

Srdan Verstovsek, MD, PhD of the MD Anderson Cancer Center in Houston, Texas discusses a middle aged man with polycythemia vera who did not respond to initial therapy (hydroxurea) with and required another treatment option. One such option is ruxolitinib which is approved for treatment of polycythemia vera in patients who have had an inadequate response to or are intolerant of hydroxyurea.

Stay informed on the latest rare disease news and developments by signing up for our newsletter.
Copyright © RareDR 2013-2019 Rare Disease Communications. All Rights Reserved.